Oncology in Images

Giant Metastatic Testicular Tumor

Szturz P., Bednařík O., Brančíková D., Mechl Z., Mayer J.

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, School of Medicine

A 53-year-old male was referred to a surgery emergency department for a suspected incarcerated inguinal hernia. Developing slowly over a period of one year, the physical examination showed a tough, right-inguinal mass (30 by 15 by 15 cm) with mild tenderness to palpation and erythematous overlying skin (Fig. 1). Furthermore, right lower extremity edema and hemiplegia on the opposite side were evident. With a general cachectic appearance (BMI = 18.9) and lethargy, the patient's other medical history was remarkable only for a smoking addiction. Laboratory investigations noted elevations of lactate dehydrogenase (46.47 ukat/L, normal range: 2.25-3.75 U/L), uric acid (610 umol/L, normal range: 202-417 umol/L), alkaline phosphatase (6.83 ukat/L, normal range: 0.67-2.15 ukat/L) and C-reactive protein (52.6 mg/L, normal range: 0–5 mg/L). Abdominal ultrasonography revealed a tumorous infiltration of the right scrotum

and pelvic area with parailiac lymphadenopathy. The pathological finding of a biopsied specimen was consistent with classical seminoma. Brain magnetic resonance imaging identified possible metastatic spread in the right basal ganglia, explaining the neurological symptomatology. The patient was not eligible for surgery and due to his poor performance status (Karnofsky score 30), he was indicated for chemotherapy in reduced dosage, which led to improved nutrition, amelioration of hemiplegia, normalization of biochemistry results and significant tumor regression (Fig. 2). Despite extensive initial tumor burden, the patient did not develop tumor lysis syndrome.

Germ cell testis tumors exceeding 400 g in weight are rare. Even in their advanced stages, cure rates exceeding 80% have been achieved using cisplatin- and carboplatin-based regimens. However, due to the side effects of cispla-

tin (nefro-, neuroand oto-toxicities), carboplatin (myeThis work was supported by project MUNI/ /A/0723/2012 and by MH CZ – DRO (FNBr, 65269705).



Petr Szturz, M.D., Ph.D.

Department of Internal Medicine, Hematology and Oncology University Hospital Brno Jihlavska 20, 625 00 Brno e-mail: petr.szturz@fnbrno.cz

Submitted/Obdrženo: 25. 6. 2013

losuppression) and bleomycin (pulmonary toxicity), their indications should be cautiously tailored to the patients' general state and comorbidities. Poor performance status and initial disease extent were identified as relevant adverse pretreatment factors in patients receiving chemotherapy containing cisplatin and bleomycin. Herein, we demonstrated encouraging therapy outcome in a patient with seriously impaired health due to a giant inoperable disseminated classical seminoma.



Fig. 1. Initial disease extent (January 2012).



Fig. 2. Effect of systemic chemotherapy (August 2012).

298 Klin Onkol 2013; 26(4): 298